A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism. - Ing SW; Finkelman RD; He P; Khan AA; Mannstadt M; Rejnmark L; Song I; Takács I; Wu Y (JBMR plus, 2023)